Document Detail


Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
MedLine Citation:
PMID:  19539099     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This study was designed to compare the efficacy and tolerability of a new generic formulation of ramipril (test) and the branded formulation of ramipril (reference) to satisfy regulatory requirements for marketing of the generic product for use in Korean patients with mild to moderate hypertension. METHODS: This was an 8-week, multicenter, prospective, randomized, open-label, parallel-group non-inferiority trial in adult patients (age > 18 years) with mild to moderate essential hypertension (sitting dia-stolic blood pressure [SiDBP] 90-109 mm Hg). After a 2-week washout of previous antihypertensive medications, eligible patients were randomized to receive either ramipril 5 mg/d in the morning (low-dose group: baseline SiDBP 90-99 mm Hg) or ramipril 10 mg/d (high-dose group: baseline SiDBP 100-109 mm Hg) for the first 4 weeks. If SiDBP was > or = 90 mm Hg after 4 weeks of treatment, the dose was increased to 10 mg/d for the remaining 4 weeks in the low-dose group, and hydrochlorothiazide 12.5 mg was added to the regimen for the remaining 4 weeks in the high-dose group. The primary end point was the change in SiDBP from baseline to week 8. Secondary end points included a noninferiority analysis of the test and reference formulations with respect to the change in mean sitting systolic blood pressure (SiSBP) from baseline to week 8; SiDBP and SiSBP response rates (proportion of patients achieving an SiDBP < 90 mm Hg and SiSBP < 140 mm Hg, respectively) at 8 weeks; and changes from baseline in SiSBP, pulse wave velocity (PWV), exercise capacity, left-ventricular diastolic function (LVDF), and levels of brain natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hs-CRP). Laboratory and clinical adverse events (AEs) were monitored at each study visit (4 and 8 weeks). RESULTS: The modified intent-to-treat population consisted of 89 patients (45 test, 44 reference; 60 men, 29 women; mean age, 49.7 years; mean weight, 69.9 kg). At week 8, mean (SD) SiSBP and SiDBP were significantly decreased from baseline in both groups (test: from 145.0 [9.7]/98.1 [5.3] mm Hg to 132.2 [11.1]/ 91.8 [7.1] mm Hg [P < 0.001]; reference: from 145.1 [11.4]/98.0 [5.7] mm Hg to 134.0 [14.6]/92.5 [7.9] mm Hg [P < 0.001]). The changes in blood pressure at week 8 did not differ significantly between the test and reference groups or between the low- and highdose groups in a subgroup analysis. Blood pressure response rates at 8 weeks did not differ significantly between the groups receiving the test and reference formulations (SiDBP: 26.7% and 31.8%, respectively; SiSBP: 37.8% and 40.9%). In addition, there were no significant between-group differences in the change in PWV (-63.8 and -38.7 cm/sec), LVDF at rest or after exercise, or levels of BNP or hs-CRP. The incidence of AEs was 64.4% in the test formulation group and 68.2% in the reference group formulation (P = NS). The most common AE in both groups was cough (10/45 [22.2%] and 10/44 [22.7%]). CONCLUSIONS: There were no significant differences in the efficacy and tolerability of the test and reference formulations of ramipril in these Korean adults with mild to moderate hypertension. The new generic formulation was noninferior to the reference formulation in terms of the change in SiDBP at week 8.
Authors:
Sang-Hyun Kim; Woo-Young Chung; Joo-Hee Zo; Myung-A Kim; Hyuk-Jae Chang; Young-Seok Cho; Tae-Jin Youn; In-Ho Chae; Dong-Joo Choi; Jae-Jin Gwak; Hae-Young Lee; Jin-Sik Park; Hyun-Jae Kang; Young-Jin Kim; Hyo-Soo Kim
Related Documents :
9017119 - Luteinizing hormone pulsatility is altered in essential hypertension.
3783849 - The need to treat mild hypertension. misinterpretation of results from the australian t...
2041039 - Training and assessment of observers for blood pressure measurement in hypertension res...
15959599 - Low frequency of target organ damage in taiwanese with white coat hypertension.
3793949 - Effectiveness of a new calcium antagonist in severe hypertension.
21769299 - Explicit control of implicit responses: simple directives can alter iat performance.
10449889 - Long-term potential of angiotensin receptor blockade for cardiovascular protection in h...
11512369 - Hemodynamic responses of thiopental and propofol in different-aged patients during endo...
1708689 - Asymmetrical effects of increases in hydrostatic pressure on macromolecular movement ac...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical therapeutics     Volume:  31     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-06-22     Completed Date:  2009-08-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  988-98     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Seoul Metropolitan Boramae Hospital, Seoul, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / adverse effects,  therapeutic use*
Blood Pressure / drug effects
C-Reactive Protein / drug effects
Chemistry, Pharmaceutical
Dose-Response Relationship, Drug
Drug Administration Schedule
Drugs, Generic / adverse effects,  therapeutic use*
Female
Humans
Hydrochlorothiazide / therapeutic use
Hypertension / drug therapy*
Korea
Male
Middle Aged
Natriuretic Peptide, Brain / blood,  drug effects
Prospective Studies
Ramipril / adverse effects,  chemistry*,  classification,  therapeutic use*
Severity of Illness Index
Treatment Outcome
Ventricular Function, Left / drug effects
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Drugs, Generic; 114471-18-0/Natriuretic Peptide, Brain; 58-93-5/Hydrochlorothiazide; 87333-19-5/Ramipril; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, r...
Next Document:  Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmacokinetics of c...